Patients with high CYP4F12 gene expression levels had a decrease in cumulative survival by 70% in bladder cancer at around 120 months, cervical cancer patients with high CYP4F12 expression showed a decrease in survival by 60% at about 140 months, and endometrial cancer patients had a decrease in survival by 55% at 120 months, HR values were 0.836, 0.736, and 1.05, respectively (Figure 10C). This evidence concerns the gene CYP4F12 and urinary bladder carcinoma.